EichorEICHOR
Condition: Wet Macular Degeneration Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Wet Macular Degeneration

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MMP-9 Inhibition for Recalcitrant Wet AMD
Phase 2 · 1 location(s) · University of Iowa · NCT04504123Gene Therapy(FT-003) for Wet AMD
Phase 1/Phase 2 · 1 location(s) · Frontera Therapeutics · NCT06492863Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
Phase 3 · 4 location(s) · Parc de Salut Mar · NCT06952452Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants
NA · 2 location(s) · Hospices Civils de Lyon · NCT04697095Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Deg
Phase 3 · 79 location(s) · Adverum Biotechnologies, Inc. · NCT07482176Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 9 location(s) · Skyline Therapeutics (US) Inc. · NCT05986864Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Phase 3 · 36 location(s) · Innostellar Biotherapeutics Co.,Ltd · NCT07317934Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Phase 4 · 1 location(s) · Medical University of Vienna · NCT05093374Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degen
Phase 2 · 12 location(s) · Adverum Biotechnologies, Inc. · NCT07630649Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macul
Phase 3 · 94 location(s) · 4D Molecular Therapeutics · NCT07064759A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Phase N/A · 10 location(s) · Skyline Therapeutics · NCT06346600Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to E
Phase 3 · 36 location(s) · King's College Hospital NHS Trust · NCT04663750AVIGA3 (Cohort 2.0)
NA · 1 location(s) · Tan Tock Seng Hospital · NCT072558594D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/Phase 2 · 25 location(s) · 4D Molecular Therapeutics · NCT05197270Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL
NA · 1 location(s) · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · NCT06893965Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Phase 1 · 7 location(s) · Caregen Co. Ltd. · NCT06132035A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degenera
Phase 1 · 3 location(s) · Youxin Chen · NCT06213038OCT Angiography in Wet AMD
Phase N/A · 1 location(s) · Oregon Health and Science University · NCT02253030Stem Cell Ophthalmology Treatment Study II
NA · 4 location(s) · MD Stem Cells · NCT03011541Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
Phase 4 · 1 location(s) · Faculty Hospital Kralovske Vinohrady · NCT06875245A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 1 location(s) · Intra-IMMUSG Pte Ltd · NCT07547228Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
Phase N/A · 1 location(s) · Beijing Anlong Biopharmaceutical Co., Ltd. · NCT06718816A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Phase 2/Phase 3 · 97 location(s) · EyeBiotech Ltd. · NCT07440225Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Wi
Phase 3 · 1 location(s) · SANGMYUNG innovation · NCT07695207A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Phase 2/Phase 3 · 71 location(s) · EyeBiotech Ltd. · NCT07496567Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Phase 1/Phase 2 · 6 location(s) · Eyconis INC. · NCT07587515A Long-term Follow up Study of EXG102-031 in Participants With wAMD
Phase N/A · 1 location(s) · Guangzhou Jiayin Biotech Ltd · NCT06859515Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
Phase 1/Phase 2 · 1 location(s) · Fujian Haixi Pharmaceuticals Co., Ltd. · NCT07185841
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.